Dipeptidyl peptidase 1 inhibitors and neutrophilic inflammation in bronchiectasis: a narrative review.

Background And Objective: Bronchiectasis is a chronic respiratory disease characterized by predominantly neutrophilic inflammation, recurrent infection and pathological dilatation of the airways. Current therapeutic strategies primarily target infections and improving mucus clearance. However, no current treatment can directly ameliorate neutrophilic inflammation.

Autologous transplantation of lung progenitor cells comes into reality for bronchiectasis.

Stem and progenitor cell-based regenerative therapies have the potential to cure chronic respiratory diseases. Yan et al. reported a clinical trial of autologous P63 progenitor cell transplantation in bronchiectasis patients, highlighting autologous transplantation of P63 progenitor cells as a novel candidate therapeutic option to improve pulmonary gas exchange function and quality of life.